← Companies|StrideBio
St

StrideBio

Durham NCFounded 201860 employees
Private CapbiotechPrivateGenetic Medicine
Platform: AAV Stealth
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
SotolucimabSTR-8350Phase 2/31RadioligandLAG-3PD-1iPV
FixatuximabSTR-192Phase 33siRNAGPRC5DPLK4iPsoriasis
RiboosocimabSTR-4038Phase 21Gene EditingTYK2STINGagPVAsthma
PolamavacamtenSTR-3449NDA/BLA1Gene TherapyHER2MeniniFabry
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)
2025-08-27
Fixatuximab Ph3 Readout
Psoriasis
Past
2026-01-05
Sotolucimab Ph3 Readout
PV
Past
2028-04-05
Fixatuximab Ph3 Readout
Psoriasis
Ph3 Readout
2029-03-02
Riboosocimab Ph2 Data
PV
Ph2 Data
2030-10-07
Polamavacamten Ph3 Readout
Fabry
Ph3 Readout
2031-12-10
Fixatuximab Ph3 Readout
Psoriasis
Ph3 Readout